Susceptibility Test and Antibacterial Drug Therapy of Burkholderia Cepacia in Our Hospital in 2007
- VernacularTitle:我院2007年洋葱伯克霍尔德菌的药敏试验结果和抗菌药物治疗分析
- Author:
Gaoqiong YAO
- Publication Type:Journal Article
- Keywords:
Burkholderia cepacia;
Antibacterials;
Susceptibility test;
Drug treatment
- From:
China Pharmacy
2007;0(26):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To monitor the resistance of clinically isolated Burkholderia cepacia and analyze its antibacterial drug therapy so as to provide reference for clinician and pharmacists in providing better treatment for the infection caused by Burkholderia cepacia. METHODS:The susceptibility test results of 17 strains of isolating Burkholderia cepacia to 12 antimicrobial agents isolated by our hospital in 2007 and the corresponding antibacterial therapeutic regimen were analyzed. RESULTS:The positive rate of Burkholderia cepacia in our hospital was 0.45%. The susceptibility test on Burkholderia cepacia showed that piperacillin /tazobactam had the highest susceptible rate with 88.2%,followed by ceftazidime at 82.4%,while Burkholderia cepacia was completely resistant to ticarcillin/ clavulanic acid or ticarcillin. The antibacterial drug treatment based on susceptibility test was effective (defined as no Burkholderia cepacia was detected in the recheck) in 9 cases(52.9%). CONCLUSION:Burkholderia cepacia is an important kind of pathogenic bacteria in nosocomial infection,and it is multidrug resistant and preferably treated by piperacillin/ tazobactam or ceftazidime.
